NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9202-9211

  Shin, Dong Mi ^a   Shaffer, Daniel J ^b,c   Wang, Hongsheng ^a   Roopenian, Derry C ^b   Morse III, Herbert C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JACKSON LABORATORY   (United States)

^c Bar Harbor BioTechnology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CANCER GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION PROFILING; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMA CELLS; PLASMACYTOMA; POLYMERASE CHAIN REACTION; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 56449088019     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6555     Document Type: Article

References (50)

1. Hartley JW, Chattopadhyay SK, Lander MR, et al. Accelerated appearance of multiple B cell lymphoma types in NFS/N mice congenic for ecotropic murine leukemia viruses. Lab Invest 2000;80:159-69.
2. Morse HC III, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002;100:246-58.
3. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005;5:251-62.
4. Potter M. Neoplastic development in plasma cells. Immunol Rev 2003;194:177-95.
5. Qi C-F, Zhou JX, Lee CH, et al. Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. Cancer Res 2007;67:2439-47.
6. Jonkers J, Berns A. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim Biophys Acta 1996;1287:29-57.
7. Shin MS, Fredrickson TN, Hartley JW, Suzuki T, Agaki K, Morse HC III. High-throughput retroviral tagging for identification of genes involved in initiation and progression of mouse splenic marginal zone lymphomas. Cancer Res 2004;64:4419-27.
8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
9. Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J, Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003; 101:1128-40.
10. Kovalchuk AL, Kim JS, Park SS, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 2002;99:1509-14.
11. Akilesh S, Shaffer DJ, Roopenian D. Customized molecular phenotyping by quantitative gene expression and pattern recognition analysis. Genome Res 2003;13: 1719-27.
12. Lee CH, Melchers M, Wang H, et al. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence-binding protein. J Exp Med 2006;203:63-72.
13. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
14. Subramanian A, Tamayo P, Mootha VK, et al. From the Cover: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102: 15545-50.
15. Maillard I, Weng AP, Carpenter AC, et al. Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 2004;104:1696-702.
16. Fredrickson TN, Lennert K, Chattopadhyay SK, Morse HC III, Hartley JW. Splenic marginal zone lymphomas of mice. Am J Pathol 1999;154:805-12.
17. Morse HC III. Classification and characteristics of mouse B cell-lineage lymphoma. In: Honjo T, Alt F, Neuberger M, editors. Molecular biology of B cells. San Diego: Elsevier Academic Press; 2004. p. 365-75.
18. Janz S, Morse HC III, Teitell M. Mouse models of human mature B cells and plasma cell neoplasm. In: Li S, editor. Mouse models of human blood cancers. Berlin (Germany): Springer Science; 2008. p. 179-226.
19. Park ES, Shaughnessy J, Gupta S, et al. Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. BMC Genomics 2007; 8:302.
20. De Vos J, Thykjaer T, Tarte K. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 2002;21:6848-57.
21. Hanamura I, Huang Y, Zhan F, Barlogie B, Shaughnessy J. Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations. Leukemia 2006;20:1288-90.
22. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-98.
23. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8:463-70.
24. Santos MA, Sarmento LM, Rebelo M, et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc Natl Acad Sci U S A 2007;104:15454-9.
25. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-6.
26. Androutsellis-Theotokis A, Leker RR, Soldner F, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006;442:823-6.
27. Ishiko E, Matsumura I, Ezoe S, et al. Notch signals inhibit the development of erythroid/megakaryocytic cells by suppressing GATA-1 activity through the induction of HES1. J Biol Chem 2005;280:4929-39.
28. Menssen A, Hermeking H. From the Cover: Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A 2002;99:6274-9.
29. Lawlor ER, Soucek L, Brown-Swigart L, Shchors K, Bialucha CU, Evan GI. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res 2006;66:4591-601.
30. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 2008;111:2220-9.
31. Zhang Z, Nadeau P, Song W, et al. Presenilins are required for γ-secretase cleavage of β-APP and transmembrane cleavage of Notch-1. Nat Cell Biol 2000;2:463-5.
32. Tanigaki K, Honjo T. Regulation of lymphocyte development by Notch signaling. Nat Immunol 2007;8: 451-6.
33. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity 1999;11:299-308.
34. Hozumi K, Negishi N, Suzuki D, et al. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat Immunol 2004;5:638-44.
35. Tanigaki K, Han H, Yamamoto N, et al. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immunol 2002;3:443-50.
36. Wu L, Maillard I, Nakamura M, Pear WS, Griffin JD. The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood 2007;110:3618-23.
37. Witt CM, Won W-J, Hurez V, Klug CA. Notch2 haploinsufficiency results in diminished B1 B cells and a severe reduction in marginal zone B cells. J Immunol 2003;171:2783-8.
38. Suzuki T, Shen H, Akagi K, et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002;32:166-74.
39. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004; 104:3697-704.
40. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood 2004;103:3503-10.
41. De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771-80.
42. Jundt F, Probsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004;103:3511-5.
43. Zweidler-McKay PA, He Y, Xu L, et al. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 2005;106: 3898-906.
44. Levens D. Disentangling the MYC web. Proc Natl Acad Sci U S A 2002;99:5757-9.
45. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 2003;100:8164-9.
46. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 2006;20:2096-109.
47. ar-Rushdi A, Nishikura K, Erikson J, Watt R, Rovera G, Croce C. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. Science 1983;222:390-3.
48. Boylan KLM, Gosse MA, Staggs SE, et al. A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma. Cancer Res 2007; 67:4069-78.
49. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398-403.
50. Shou Y, Martelli ML, Gabrea A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97: 228-33.